
Endocrinology & Metabolism
Teplizumab Expands to Pediatric Stage 3 Type 1 Diabetes
The FDA expanded teplizumab to patients ages 8–17 with stage 3 type 1 diabetes diagnosed within six weeks, based on evidence that it slows loss of insulin-producing function.
Rayan Salih · August 17, 2026 · 7 min

